Background: Adverse radiation effect (ARE) is one of the complications of stereotactic radiosurgery. Its treatment with conventional medications, such as corticosteroids, vitamin E, and pentoxifylline carries a high risk of failure, with up to 20% of lesions refractory to such medications. In addition, deep lesions and those occurring in patients with significant medical comorbidities may not be suitable for surgical resection. Bevacizumab is an antiangiogenic monoclonal antibody against vascular endothelial growth factor, a known mediator of cerebral edema. It can be used to successfully treat ARE. Case Description: An 85-year-old man with a history of small-cell lung cancer presented with metastatic disease to the brain. He underwent stereotactic radiosurgery to a brain metastasis involving the right external capsule. Three months later, the lesion had increased in size, with significant surrounding edema. The patient developed an adverse reaction to steroid treatment and had a poor response to treatment with pentoxifylline and vitamin E. He was deemed a poor surgical candidate because of his medical comorbidities. He was eventually treated with 3 doses of bevacizumab, and the treatment resulted in significant clinical improvement. Magnetic resonance imaging showed some decrease in the size of the lesion and significant decrease in the surrounding edema. Conclusions: Bevacizumab can be successfully used to treat ARE induced by stereotactic radiosurgery in patients with cerebral metastases. It is of particular benefit in patients considered unsuitable for surgical decompression. It is also beneficial in patients with poor tolerance to corticosteroids and in patients who do not respond to other medications.
INRODUCTION
Adverse radiation effect (ARE) is one of the complications of stereotactic radiosurgery. [7] The pathophysiology of ARE involves damage to vascular endothelial cells, with subsequent vessel occlusion and coagulation necrosis. [8] Symptoms are caused by surrounding vasogenic edema and subsequent mass effect. Medical management of ARE includes corticosteroids, vitamin E, and pentoxifylline. [2, 8] However, these treatments were not significantly effective in randomized controlled trials, with up to 20% of lesions refractory to medical treatment. [2, 8] Surgical decompression has been used for symptomatic lesions refractory to medical management. [11] Recent reports suggest that deep lesions that are not readily accessible by a surgical corridor may be treated with laser-interstitial thermal therapy. [3, 5, 9] However, those lesions occurring in patients with significant medical comorbidities may not be suitable for surgical intervention.
Bevacizumab is an antiangiogenic monoclonal antibody against vascular endothelial growth factor, a known mediator of cerebral edema. Bevacizumab was shown to be effective in the treatment of radiation-induced necrosis in patients with brain tumors. [8] 
CASE REPORT
An 85-year old man with a history of small-cell lung cancer presented with metastatic disease to the brain. The patient was initially treated with dexamethasone but developed significant proximal muscle weakness. He was then started on pentoxifylline and vitamin E but continued to experience significant deterioration in his activities of daily living. The patient was deemed a poor surgical candidate because of advanced congestive heart failure with low ejection fraction, superior vena cava syndrome, and carotid stenosis. However, his systemic disease remained under good control. He was treated with 3 doses of bevacizumab (7.5 mg/kg every 3 weeks for 12 weeks). Of note, the bevacizumab doses were covered by the patient's health maintenance organization. Treatment resulted in significant improvement in activities of daily living, and the patient became functionally independent following the completion of the 3 treatment doses. MRI showed some decrease in the size of the lesion and a significant decrease in the surrounding edema [ Figure 1 right] .
DISCUSSION
This case describes a significant size increase in a brain metastasis following stereotactic radiosurgery. There is no noninvasive diagnostic study to differentiate tumor recurrence from ARE in post-stereotactic radiosurgery brain metastases. [6] The lesion's rapid increase in size over a 3-month period suggested a diagnosis of ARE. Compared with the patient's original brain MRI study (before stereotactic radiosurgery), the study obtained on the day of stereotactic radiosurgery suggested a tumor growth rate that alone could not account for such rapid lesion growth. An ARE peak 3 months post-stereotactic radiosurgery has previously been described. [4] Symptomatic post-stereotactic radiosurgery brain metastases should be treated. [6] For patients who are not surgical candidates, bevacizumab is an option. Although typically well-tolerated, side effects can include poor wound healing, intestinal perforation, and cerebrovascular accident. [10] Recent bevacizumab use is an absolute contraindication to many surgical procedures. [1] In addition, there is a significant cost to this medication, and it may not always be covered by a health maintenance organization. In patients with symptomatic ARE who are not surgical candidates, bevacizumab does provide a nonsurgical treatment option. The use of prolonged corticosteroid therapy for ARE should be avoided due to significant steroid-related toxicities. Such nonsurgical patients who are symptomatic after stereotactic radiosurgery for brain metastasis should be evaluated for bevacizumab therapy.
CONCLUSION
Bevacizumab can successfully be used to treat ARE induced by stereotactic radiosurgery in patients with cerebral metastases. It is of particular benefit in patients unsuitable for surgical decompression. Rather than a prolonged course of corticosteroids, patients with post-stereotactic radiosurgery ARE should be evaluated for bevacizumab therapy.
